Related Content
June 13, 2013 โ Abbott announced publication of positive outcomes from two European post-approval studies of the ...
Interventional cardiology treats cardiovascular disease, an illness currently afflicting one in every three Americans ...
May 28, 2013 โ Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System ...
April 18, 2013 โ Abbott has received Conformite Europeene (CE) marking for the Architect Galectin-3 assay, a blood test ...
March 22, 2013 โ Abbott announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of ...
March 15, 2013 โ Abbott announced positive long-term results for the company's innovative Absorb Bioresorbable Vascular ...
February 22, 2013 โ Physicians have new tools for treating coronary chronic total occlusions (CTOs) after Abbott ...
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents ...
January 30, 2013 โ January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData ...
January 29, 2013 โ An estimated 17 million people throughout the world die annually of cardiovascular diseases ...